AU2002217078A1 - Urea and urethane derivatives as integrin inhibitors - Google Patents

Urea and urethane derivatives as integrin inhibitors

Info

Publication number
AU2002217078A1
AU2002217078A1 AU2002217078A AU1707802A AU2002217078A1 AU 2002217078 A1 AU2002217078 A1 AU 2002217078A1 AU 2002217078 A AU2002217078 A AU 2002217078A AU 1707802 A AU1707802 A AU 1707802A AU 2002217078 A1 AU2002217078 A1 AU 2002217078A1
Authority
AU
Australia
Prior art keywords
urea
integrin inhibitors
urethane derivatives
urethane
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002217078A
Inventor
Simon Goodman
Alfred Jonczyk
Oliver Schadt
Wolfgang Staehle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2002217078A1 publication Critical patent/AU2002217078A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
AU2002217078A 2000-12-18 2001-11-30 Urea and urethane derivatives as integrin inhibitors Abandoned AU2002217078A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10063173A DE10063173A1 (en) 2000-12-18 2000-12-18 Urea and urethane derivatives
DE10063173 2000-12-18
PCT/EP2001/014039 WO2002050039A1 (en) 2000-12-18 2001-11-30 Urea and urethane derivatives as integrin inhibitors

Publications (1)

Publication Number Publication Date
AU2002217078A1 true AU2002217078A1 (en) 2002-07-01

Family

ID=7667710

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002217078A Abandoned AU2002217078A1 (en) 2000-12-18 2001-11-30 Urea and urethane derivatives as integrin inhibitors

Country Status (23)

Country Link
US (1) US7135587B2 (en)
EP (1) EP1343764B1 (en)
JP (1) JP4216071B2 (en)
KR (1) KR20030063432A (en)
CN (1) CN1481364A (en)
AR (1) AR035608A1 (en)
AT (1) ATE274497T1 (en)
AU (1) AU2002217078A1 (en)
BR (1) BR0116202A (en)
CA (1) CA2431974C (en)
CZ (1) CZ20031775A3 (en)
DE (2) DE10063173A1 (en)
DK (1) DK1343764T3 (en)
ES (1) ES2227063T3 (en)
HU (1) HUP0302753A3 (en)
MX (1) MXPA03005431A (en)
NO (1) NO20032754D0 (en)
PL (1) PL361745A1 (en)
PT (1) PT1343764E (en)
RU (1) RU2003121015A (en)
SK (1) SK8182003A3 (en)
WO (1) WO2002050039A1 (en)
ZA (1) ZA200305550B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10204789A1 (en) 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitors of the integrin alpha¶v¶beta6
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
DE602004014795D1 (en) * 2003-10-01 2008-08-14 Merck Patent Gmbh ALFAVBETA3 AND ALFAVBETA6 INTEGRIN ANTAGONISTS AS ANTIFIBROTIC AGENTS
CN102875681A (en) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 Anti-alpha v beta 6 antibodies and uses thereof
EP2046374A4 (en) 2006-07-10 2010-05-05 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
AU2007354317A1 (en) * 2006-10-19 2008-12-04 Biogen Idec Ma Inc. Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6
AT509266B1 (en) * 2009-12-28 2014-07-15 Tech Universität Wien SUBSTITUTED PYRIDINES AND PYRIMIDINES
CN102353728B (en) * 2011-06-29 2013-03-27 中国食品发酵工业研究院 Rapid detection method for production process quality control of yellow wine
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
NZ740675A (en) 2015-10-23 2024-02-23 Vifor Int Ag Novel ferroportin inhibitors
JOP20180036A1 (en) 2017-04-18 2019-01-30 Vifor Int Ag Novel ferroportin-inhibitor salts

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
KR20010042704A (en) * 1998-04-16 2001-05-25 데이비드 비. 맥윌리암스 N,N-Disubstituted amides that inhibit the binding of integrins to their receptors
GB9909409D0 (en) 1999-04-24 1999-06-23 Zeneca Ltd Chemical compounds
DE19939980A1 (en) * 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitors of the integrin alphavbeta¶3¶

Also Published As

Publication number Publication date
ATE274497T1 (en) 2004-09-15
CA2431974C (en) 2010-08-17
WO2002050039A1 (en) 2002-06-27
US20040063644A1 (en) 2004-04-01
SK8182003A3 (en) 2003-10-07
NO20032754L (en) 2003-06-17
MXPA03005431A (en) 2003-09-10
HUP0302753A2 (en) 2003-12-29
CN1481364A (en) 2004-03-10
AR035608A1 (en) 2004-06-16
DE60105192T2 (en) 2005-09-08
DE60105192D1 (en) 2004-09-30
DK1343764T3 (en) 2004-12-06
DE10063173A1 (en) 2002-06-20
JP2004516282A (en) 2004-06-03
CA2431974A1 (en) 2002-06-27
CZ20031775A3 (en) 2003-09-17
HUP0302753A3 (en) 2005-03-29
PT1343764E (en) 2005-01-31
ZA200305550B (en) 2004-10-18
JP4216071B2 (en) 2009-01-28
ES2227063T3 (en) 2005-04-01
RU2003121015A (en) 2005-02-10
EP1343764B1 (en) 2004-08-25
NO20032754D0 (en) 2003-06-17
US7135587B2 (en) 2006-11-14
KR20030063432A (en) 2003-07-28
EP1343764A1 (en) 2003-09-17
PL361745A1 (en) 2004-10-04
BR0116202A (en) 2003-12-23

Similar Documents

Publication Publication Date Title
AU2001262089A1 (en) Alpha4beta1 and alpha4beta7 integrin inhibitors
AU5379900A (en) Thiophene integrin inhibitors
AU5991699A (en) Quinolizinones as integrin inhibitors
AU5134499A (en) Amide, carbamate, and urea derivatives
AU2002230836A1 (en) Benzylamine derivatives and their use as thrombin inhibitors
PL356427A1 (en) Indol-3-yl derivatives and their use as integrin inhibitors
AU4276599A (en) Phenylalanine derivatives as integrin inhibitors
AU5066900A (en) Benzimidazole derivatives and their use as methionyl t-rna synthetase inhibitors
AU2002217078A1 (en) Urea and urethane derivatives as integrin inhibitors
AU2001286242A1 (en) Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient
AU2002214166A1 (en) 1-sulfonyl substituted tryptophane derivatives and its use as integrin inhibitors
PL349769A1 (en) New amidinobenzylamine derivatives and their use as thrombin inhibitors
AU2002211662A1 (en) Nf-kappab inhibitors
AU5213300A (en) 2-nh-pyridones and pyrimidones as mrs inhibitors
AU2001244596A1 (en) Indolylpyrrole derivatives and cell death inhibitors
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors
AU5693101A (en) New thiochromane derivatives and their use as thrombin inhibitors
AU2002216650A1 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
AU4501199A (en) 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
AU6992500A (en) Alphavbeta3 integrin inhibitors
AU2001277561A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
AU2001266124A1 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
AU3595900A (en) Tyrosine alkoxyguanidines as integrin inhibitors
HK1049666A1 (en) NOVEL INTEGRIN α V β INHIBITORS
AU2001235364A1 (en) Tetrahydronaphtalene derivatives and their use